Neomycin alone can reduce postprandial blood glucose levels, and may enhance the reduction in postprandial glucose levels associated with
acarbose.
Neomycin also appears to increase the unpleasant
gastrointestinal adverse effects (flatulence, cramps and diarrhoea) of
acarbose.
The manufacturers suggest that if these adverse effects are severe the dosage of
acarbose should be reduced.